TNFSF11 and systemic mastocytosis: Bone loss in SM may occur through the receptor activator of nuclear factor κ-B ligand (RANKL) system; therefore, denosumab is theoretically preferable to intravenous bisphosphonates based on mechanism and quick onset of action (26, 28).